Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

207.77
-0.2600-0.12%
Post-market: 207.770.00000.00%19:30 EDT
Volume:734.95K
Turnover:153.13M
Market Cap:10.88B
PE:-55.13
High:210.87
Open:207.22
Low:206.50
Close:208.03
52wk High:260.19
52wk Low:112.90
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.37
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:130.64
PE(LYR):-56.43

Loading ...

CervoMed Q2 Net Loss Lower than Estimates as Costs Drop

Reuters
·
Aug 10

Axsome Therapeutics reports Q2 EPS (99c), consensus (85c)

TIPRANKS
·
Aug 10

Axsome Therapeutics Q2 Loss Widens, Revenue Increases

MT Newswires Live
·
Aug 10

Axsome Therapeutics Q2 Revenue Rises on Auvelity Growth

Reuters
·
Aug 10

Axsome Therapeutics Shares Down 8.4% Premarket After Q2 Revenue Miss

THOMSON REUTERS
·
Aug 10

Axsome Q2 FY26 Net Loss Widens to $51.3 Million; Net Product Revenue Climbs 46% to $218.4 Million Year over Year

Reuters
·
Aug 10

Stock Track | Axsome Therapeutics Plunges 5.99% in Pre-market After Q2 Earnings Miss Estimates

Stock Track
·
Aug 10

Earnings Flash (AXSM) Axsome Therapeutics Posts Q2 Loss $0.99 a Share, vs. FactSet Est of $0.89 Loss

MT Newswires Live
·
Aug 10

Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate

Benzinga Earnings
·
Aug 10

Axsome Therapeutics Q2 Net Income USD -51.314 Million

Reuters
·
Aug 10

Axsome Therapeutics Q2 EPS USD -0.99

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics Q2 Operating Expenses USD 268.021 Million

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS
·
Aug 10

Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build

Simply Wall St.
·
Aug 10

Axsome CEO Herriot Tabuteau Disposes of USD 10.54 Million in Common Shares

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 07

Is Axsome Therapeutics (AXSM) Trading Profitability for Pipeline Expansion As Revenue Outpaces Earnings?

Simply Wall St.
·
Aug 04

Earning Preview: Axsome Therapeutics revenue is expected to increase by 59.29%, and institutional views are predominantly bullish

Earnings Agent
·
Aug 03

Axsome Therapeutics is Maintained at Outperform by Mizuho

Dow Jones
·
Aug 01

Mizuho Trims Price Target on Axsome Therapeutics to $306 From $310, Keeps Outperform Rating

MT Newswires Live
·
Jul 31